Leukemia Research Reports最新文献

英文中文

Case report: Experience of a rare case of primary acute mast cell leukemia 病例报告：一例罕见的原发性急性肥大细胞白血病

IF 0.7 Q4 HEMATOLOGY

Leukemia Research Reports

Pub Date : 2025-01-01 Epub Date: 2025-04-12 DOI: 10.1016/j.lrr.2025.100510

Zhijuan Pan, Ying Zhang, Yanru Guo, Jiajia Sun, Xinlei Guo, Zhiping Guo

Backgrounds

Mast cell leukemia (MCL) is a rare and aggressive form of systemic mastocytosis with a poor prognosis. Understanding the different therapeutic responses to corticosteroids in MCL is crucial for improving patient outcomes.

Case presentation

We present a case of a 74-year-old Chinese female with primary acute MCL who exhibited different responses to dexamethasone and methylprednisolone. She was admitted with persistent fever, dyspnea, severe fatigue, and bone pain, alongside splenomegaly and cytopenia. Diagnosis was confirmed through marrow aspirate analysis, chemical staining, flow cytometry, and biopsy, revealing atypical mast cells positive for CD117, CD9, CD81, CD33, CD13, CD4, and partially for CD56, but negative for CD2 and CD25. Next-generation sequencing identified heterozygous mutations in NRAS, DNMT3A, and TP53, with no KIT mutations. Initial treatment included corticosteroids and dasatinib. The patient showed a partial response to dexamethasone but significant improvement with methylprednisolone. Upon reintroduction of dexamethasone, symptoms recurred, which improved again after resuming methylprednisolone. The patient survived for three months post-diagnosis.

Conclusion

This case highlights the potential efficacy of methylprednisolone over dexamethasone in MCL treatment. This case underscores the importance of personalized treatment approaches in MCL, considering the distinct genetic profile and differential therapeutic responses to corticosteroids. Further research is needed to elucidate the mechanisms underlying these responses and to optimize treatment strategies for MCL.

细胞白血病（MCL）是一种罕见的侵袭性系统性肥大细胞增多症，预后较差。了解MCL患者对皮质类固醇的不同治疗反应对于改善患者预后至关重要。我们报告一例74岁的中国女性原发性急性MCL患者，她对地塞米松和甲基强的松龙表现出不同的反应。患者入院时伴有持续发热、呼吸困难、严重疲劳和骨痛，同时伴有脾肿大和细胞减少。通过骨髓抽吸分析、化学染色、流式细胞术和活检证实诊断，发现非典型肥大细胞CD117、CD9、CD81、CD33、CD13、CD4阳性，部分CD56阳性，但CD2和CD25阴性。下一代测序鉴定出NRAS、DNMT3A和TP53的杂合突变，没有KIT突变。初始治疗包括皮质类固醇和达沙替尼。患者对地塞米松有部分反应，但对甲基强的松龙有明显改善。重新使用地塞米松后，症状复发，恢复使用甲基强的松龙后症状再次改善。患者在确诊后存活了三个月。结论该病例突出了甲基强的松龙治疗MCL的潜在疗效优于地塞米松。考虑到不同的遗传特征和对皮质类固醇的不同治疗反应，该病例强调了MCL个性化治疗方法的重要性。需要进一步的研究来阐明这些反应的机制并优化MCL的治疗策略。

{"title":"Case report: Experience of a rare case of primary acute mast cell leukemia","authors":"Zhijuan Pan, Ying Zhang, Yanru Guo, Jiajia Sun, Xinlei Guo, Zhiping Guo","doi":"10.1016/j.lrr.2025.100510","DOIUrl":"10.1016/j.lrr.2025.100510","url":null,"abstract":"<div><h3>Backgrounds</h3><div>Mast cell leukemia (MCL) is a rare and aggressive form of systemic mastocytosis with a poor prognosis. Understanding the different therapeutic responses to corticosteroids in MCL is crucial for improving patient outcomes.</div></div><div><h3>Case presentation</h3><div>We present a case of a 74-year-old Chinese female with primary acute MCL who exhibited different responses to dexamethasone and methylprednisolone. She was admitted with persistent fever, dyspnea, severe fatigue, and bone pain, alongside splenomegaly and cytopenia. Diagnosis was confirmed through marrow aspirate analysis, chemical staining, flow cytometry, and biopsy, revealing atypical mast cells positive for CD117, CD9, CD81, CD33, CD13, CD4, and partially for CD56, but negative for CD2 and CD25. Next-generation sequencing identified heterozygous mutations in <em>NRAS, DNMT3A</em>, and <em>TP5</em>3, with no <em>KIT</em> mutations. Initial treatment included corticosteroids and dasatinib. The patient showed a partial response to dexamethasone but significant improvement with methylprednisolone. Upon reintroduction of dexamethasone, symptoms recurred, which improved again after resuming methylprednisolone. The patient survived for three months post-diagnosis.</div></div><div><h3>Conclusion</h3><div>This case highlights the potential efficacy of methylprednisolone over dexamethasone in MCL treatment. This case underscores the importance of personalized treatment approaches in MCL, considering the distinct genetic profile and differential therapeutic responses to corticosteroids. Further research is needed to elucidate the mechanisms underlying these responses and to optimize treatment strategies for MCL.</div></div>","PeriodicalId":38435,"journal":{"name":"Leukemia Research Reports","volume":"23 ","pages":"Article 100510"},"PeriodicalIF":0.7,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143837824","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Extramedullary breast infiltration as the initial manifestation of adult acute B-lymphoblastic leukemia with TCF3::PBX1 fusion gene recurrence and adenofibroma: A case report 以乳腺髓外浸润为首发表现的成人急性b淋巴细胞白血病合并TCF3::PBX1融合基因复发及腺纤维瘤1例

IF 0.9 Q4 HEMATOLOGY

Leukemia Research Reports

Pub Date : 2025-01-01 Epub Date: 2025-11-25 DOI: 10.1016/j.lrr.2025.100552

Liya Liu , Ying Yu , Xueyan Chen

Extramedullary breast relapse of leukemia is uncommon and primarily occurs in cases of acute myeloid leukemia(AML), and secondary acute lymphoblastic leukemia (ALL) affecting the breast may also occur occasionally. The mechanism of extramedullary involvement remains unclear; patients' risk of hematological recurrence is high. TCF3::PBX1 (also known as E2A:: PBX1) is an oncogenic transcription factor arising from the T (1; 19) (q23; P13) translocation, observed in 5 % to 6 % of childhood acute lymphoblastic leukemia (ALL) cases and approximately 3 % of adult ALL cases. Here, we report a case of B-ALL with TCF3::PBX1 fusion gene, where extramedullary breast infiltration was the earliest clinical indication of recurrence. Adult ALL with the TCF3::PBX1 fusion gene is relatively uncommon compared to other ALL. Despite the satisfactory effect of chemotherapy, the patient ultimately decided to discontinue treatment following breast infiltration by ALL.

髓外乳腺癌白血病复发并不常见，主要发生在急性髓性白血病（AML）病例中，偶尔也会发生继发性急性淋巴细胞白血病（ALL）。髓外受累的机制尚不清楚；患者血液学复发的风险高。TCF3::PBX1（也称为E2A:: PBX1）是一种由T (1; 19) （q23; P13）易位引起的致癌转录因子，在5%至6%的儿童急性淋巴细胞白血病（ALL）病例和约3%的成人ALL病例中观察到。在此，我们报告一例伴有TCF3::PBX1融合基因的B-ALL，其髓外乳腺浸润是复发的最早临床指征。与其他ALL相比，携带TCF3::PBX1融合基因的成人ALL相对罕见。尽管化疗效果令人满意，但在ALL浸润乳房后，患者最终决定停止治疗。

引用次数: 0

Non-coding RNAs: Emerging contributors to chemoresistance in chronic myeloid leukemia 非编码rna：慢性髓性白血病化疗耐药的新贡献者

IF 0.7 Q4 HEMATOLOGY

Leukemia Research Reports

Pub Date : 2025-01-01 Epub Date: 2025-05-09 DOI: 10.1016/j.lrr.2025.100513

Laya Ghadyani nejhad , Mahsa Sohani , Nasrin Alizad Ghandforoush , Mohsen Nikbakht , Saeed Mohammadi , Mohammad Vaezi , Shahrbano Rostami , Bahram Chahardouli

Chronic myeloid leukemia (CML), is a myeloproliferative disease characterized by unregulated growth of blood forming cells in bone marrow and blood. The t(9;22)(q34;q11.2) translocation, which results in the formation of a hyperactive tyrosine kinase (BCR-ABL), is a hallmark of this disorder. Tyrosine kinase inhibitors such as imatinib has shown a great promise in reduction of CML cells. However, development of resistance to tyrosine kinase inhibitors has raised a great clinical concern about their future applications. Recently, non-coding RNAs, have shown to play significant regulatory roles in development of chemoresistance in CML cells. Discovering the underlying mechanisms of these non-coding RNAs might provide new opportunities for treating chemo-resistant forms of CML. These non-coding RNAs could be considered valuable therapeutic targets if they are found to play a role in the development of chemoresistance in CML cells. We mentioned the identified non-coding RNAs in development of chemoresistance in CML cells.

慢性髓性白血病（CML）是一种骨髓增生性疾病，其特征是骨髓和血液中造血细胞生长不正常。t(9;22)（q34;q11.2）易位导致过度活跃的酪氨酸激酶（BCR-ABL）的形成，是这种疾病的一个标志。酪氨酸激酶抑制剂如伊马替尼在减少CML细胞方面显示出很大的希望。然而，对酪氨酸激酶抑制剂的耐药性的发展引起了对其未来应用的极大关注。近年来，非编码rna在CML细胞的化疗耐药发展中发挥了重要的调节作用。发现这些非编码rna的潜在机制可能为治疗耐药形式的CML提供新的机会。如果发现这些非编码rna在CML细胞的化疗耐药发展中起作用，则它们可能被认为是有价值的治疗靶点。我们提到了已鉴定的非编码rna在CML细胞化疗耐药发展中的作用。

{"title":"Non-coding RNAs: Emerging contributors to chemoresistance in chronic myeloid leukemia","authors":"Laya Ghadyani nejhad , Mahsa Sohani , Nasrin Alizad Ghandforoush , Mohsen Nikbakht , Saeed Mohammadi , Mohammad Vaezi , Shahrbano Rostami , Bahram Chahardouli","doi":"10.1016/j.lrr.2025.100513","DOIUrl":"10.1016/j.lrr.2025.100513","url":null,"abstract":"<div><div>Chronic myeloid leukemia (CML), is a myeloproliferative disease characterized by unregulated growth of blood forming cells in bone marrow and blood. The t(9;22)(q34;q11.2) translocation, which results in the formation of a hyperactive tyrosine kinase (<em>BCR-ABL</em>), is a hallmark of this disorder. Tyrosine kinase inhibitors such as imatinib has shown a great promise in reduction of CML cells. However, development of resistance to tyrosine kinase inhibitors has raised a great clinical concern about their future applications. Recently, non-coding RNAs, have shown to play significant regulatory roles in development of chemoresistance in CML cells. Discovering the underlying mechanisms of these non-coding RNAs might provide new opportunities for treating chemo-resistant forms of CML. These non-coding RNAs could be considered valuable therapeutic targets if they are found to play a role in the development of chemoresistance in CML cells. We mentioned the identified non-coding RNAs in development of chemoresistance in CML cells.</div></div>","PeriodicalId":38435,"journal":{"name":"Leukemia Research Reports","volume":"23 ","pages":"Article 100513"},"PeriodicalIF":0.7,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143947518","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Involvement of the central nervous system in relapsed T-cell lymphoma: insights from four case studies 复发性t细胞淋巴瘤累及中枢神经系统：来自四个病例研究的见解

IF 0.7 Q4 HEMATOLOGY

Leukemia Research Reports

Pub Date : 2025-01-01 Epub Date: 2025-06-23 DOI: 10.1016/j.lrr.2025.100524

Radu Chiriac, Lucile Baseggio

CNS involvement in T-cell lymphoma is rare, with a 2–6 % risk of relapse. This report presents four cases of CNS relapse in aggressive T-cell lymphomas, including PTCL NOS, AITL, ALCL ALK (-), and ENKTCL. Patients experienced severe neurological symptoms, elevated CSF WBC counts, and resistance to various treatment regimens, including intrathecal HD MTX, salvage chemotherapy, and immunotherapy. Median survival was 1.5–3.5 months, highlighting the poor prognosis. The findings highlight the complexities of managing CNS relapse, the evolving understanding of prophylactic strategies, and the potential for innovative, targeted therapeutic combinations to enhance outcomes for these high-risk patients.

中枢神经系统受累于t细胞淋巴瘤是罕见的，复发的风险为2 - 6%。本文报告4例侵袭性t细胞淋巴瘤的中枢神经系统复发，包括PTCL NOS、AITL、ALCL ALK（-）和ENKTCL。患者出现严重的神经系统症状，脑脊液白细胞计数升高，并对各种治疗方案产生耐药性，包括鞘内注射HD MTX、补救性化疗和免疫治疗。中位生存期为1.5-3.5个月，预后较差。研究结果强调了控制中枢神经系统复发的复杂性，对预防策略的不断发展的理解，以及创新的靶向治疗组合的潜力，以提高这些高风险患者的预后。

引用次数: 0

Indolent peripheral T-cell lymphoma resembling Kimura's disease: a new variant of T-cell Lymphoma? 类似木村病的惰性外周t细胞淋巴瘤：一种新的t细胞淋巴瘤变体？

IF 0.9 Q4 HEMATOLOGY

Leukemia Research Reports

Pub Date : 2025-01-01 Epub Date: 2025-09-19 DOI: 10.1016/j.lrr.2025.100547

Hui Sun , Jia Feng , Yaping Zhang , Jianguo Zhang , Shaolei Lu , Yifei Liu

Kimura's disease (KD) is a rare chronic inflammatory disorder of unknown etiology prevalent in middle-aged Asian males. Kimura's disease transforming to T-cell lymphoma or coexisting with T-cell lymphoma have not been reported in the scientific literature except two cases of Kimura's disease resembling peripheral T-cell lymphoma morphologically. There was no corresponding entity included in the current WHO classification (5th ed., 2022). It might be a new variant of peripheral T-cell lymphoma. Here, we present the first reported case of coexisting KD and indolent peripheral T-cell lymphoma in a 55-year-old Chinese man.

木村病（KD）是一种罕见的慢性炎症性疾病，病因不明，常见于亚洲中年男性。木村病转化为t细胞淋巴瘤或与t细胞淋巴瘤共存，除两例形态学上类似外周t细胞淋巴瘤的木村病外，尚未见科学文献报道。目前的世卫组织分类（第5版，2022年）中没有相应的实体。它可能是一种新的外周t细胞淋巴瘤。在这里，我们报告了一例55岁的中国男性并发KD和惰性外周t细胞淋巴瘤的病例。

引用次数: 0

Fatal case of disseminated toxoplasmosis following allogeneic stem cell transplantation in Singapore – a case report and review of literature 新加坡异体干细胞移植后弥散性弓形虫病致死病例报告及文献复习

IF 0.9 Q4 HEMATOLOGY

Leukemia Research Reports

Pub Date : 2025-01-01 Epub Date: 2025-09-10 DOI: 10.1016/j.lrr.2025.100545

Jinghao Nicholas Ngiam , Thuan Tong Tan , Ban Hock Tan , Wenlu Hou , Aloysius Yew Leng Ho , Jeffrey Kim Siang Quek , Yeh Ching Linn , Francesca Lorraine Wei Inng Lim , Hein Than , Shimin Jasmine Chung

Toxoplasmosis is a rare but potentially fatal complication post-allogeneic hematopoietic stem cell transplantation (HSCT), often due to latent reactivation. In Singapore, low seroprevalence limits routine screening and prophylaxis. We report the first reported case of disseminated toxoplasmosis following HSCT in Singapore. A 58-year-old woman with fever and altered mental status two months post-transplant. She had pancytopenia, acute kidney injury, and pneumonitis, with non-specific brain MRI findings. Toxoplasma polymerase chain reaction from serum, bone marrow, and cerebrospinal fluid was positive. Despite treatment with trimethoprim-sulfamethoxazole, pyrimethamine, and sulfadiazine, she developed seizures, intracranial haemorrhage, and nosocomial infections, ultimately succumbing one month later. This case potentially highlights the consideration of routine pre-transplant Toxoplasma screening and prevention strategies, even in regions with low seroprevalence.

弓形虫病是异体造血干细胞移植（HSCT）后罕见但潜在致命的并发症，通常是由于潜在的再激活。在新加坡，低血清阳性率限制了常规筛查和预防。我们在新加坡报道首例HSCT后播散性弓形虫病病例。一名58岁女性，移植后两个月出现发热和精神状态改变。她有全血细胞减少症、急性肾损伤和肺炎，并有非特异性脑MRI发现。血清、骨髓、脑脊液弓形虫聚合酶链反应阳性。尽管接受了甲氧苄啶-磺胺甲恶唑、乙胺嘧啶和磺胺嘧啶治疗，她仍出现癫痫发作、颅内出血和院内感染，最终在一个月后死亡。该病例潜在地强调了移植前常规弓形虫筛查和预防策略的考虑，即使在血清阳性率较低的地区也是如此。

{"title":"Fatal case of disseminated toxoplasmosis following allogeneic stem cell transplantation in Singapore – a case report and review of literature","authors":"Jinghao Nicholas Ngiam , Thuan Tong Tan , Ban Hock Tan , Wenlu Hou , Aloysius Yew Leng Ho , Jeffrey Kim Siang Quek , Yeh Ching Linn , Francesca Lorraine Wei Inng Lim , Hein Than , Shimin Jasmine Chung","doi":"10.1016/j.lrr.2025.100545","DOIUrl":"10.1016/j.lrr.2025.100545","url":null,"abstract":"<div><div>Toxoplasmosis is a rare but potentially fatal complication post-allogeneic hematopoietic stem cell transplantation (HSCT), often due to latent reactivation. In Singapore, low seroprevalence limits routine screening and prophylaxis. We report the first reported case of disseminated toxoplasmosis following HSCT in Singapore. A 58-year-old woman with fever and altered mental status two months post-transplant. She had pancytopenia, acute kidney injury, and pneumonitis, with non-specific brain MRI findings. Toxoplasma polymerase chain reaction from serum, bone marrow, and cerebrospinal fluid was positive. Despite treatment with trimethoprim-sulfamethoxazole, pyrimethamine, and sulfadiazine, she developed seizures, intracranial haemorrhage, and nosocomial infections, ultimately succumbing one month later. This case potentially highlights the consideration of routine pre-transplant Toxoplasma screening and prevention strategies, even in regions with low seroprevalence.</div></div>","PeriodicalId":38435,"journal":{"name":"Leukemia Research Reports","volume":"24 ","pages":"Article 100545"},"PeriodicalIF":0.9,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145094823","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

When the mask slips: A peripheral T-cell lymphoma disguised as lupus with myelofibrosis in a patient with May-Hegglin syndrome 当面具滑落梅-赫格林综合征患者伪装成狼疮伴骨髓纤维化的外周 T 细胞淋巴瘤。

IF 0.7 Q4 HEMATOLOGY

Leukemia Research Reports

Pub Date : 2025-01-01 Epub Date: 2024-12-20 DOI: 10.1016/j.lrr.2024.100498

V Da Silva Constante , H Couvert , A Wolfromm , M Ilzkovitz

We describe the case of a female patient with May-Hegglin syndrome who developed peripheral T-cell lymphoma not otherwise specified. The patient presents with systemic lupus erythematous phenotype and myelofibrosis secondary to T-cell lymphoma. Peripheral T-cell lymphoma not otherwise specified, represents 25 % of all peripheral T-cell lymphoma. Its diagnosis remains challenging due to the polymorphous clinical presentation and pathological heterogeneity. Myelofibrosis associated with malignant lymphomas is rare and peripheral T-cell lymphoma is even rarer. To our knowledge, this is the first case to describe an association between May-Hegglin syndrome and a peripheral T-cell lymphoma.

我们描述的情况下，女性患者与梅- hegglin综合征谁发展外周t细胞淋巴瘤没有其他规定。患者表现为系统性红斑狼疮和继发于t细胞淋巴瘤的骨髓纤维化。外周t细胞淋巴瘤，未另行说明，占所有外周t细胞淋巴瘤的25%。由于多形性临床表现和病理异质性，其诊断仍然具有挑战性。骨髓纤维化与恶性淋巴瘤相关是罕见的，周围t细胞淋巴瘤更罕见。据我们所知，这是第一例描述May-Hegglin综合征和外周t细胞淋巴瘤之间关系的病例。

引用次数: 0

Impact of PD-1 and PD-L1 expression on treatment outcomes in newly diagnosed acute myeloid leukemia patients PD-1和PD-L1表达对新诊断急性髓性白血病患者治疗结果的影响

IF 0.7 Q4 HEMATOLOGY

Leukemia Research Reports

Pub Date : 2025-01-01 Epub Date: 2025-05-09 DOI: 10.1016/j.lrr.2025.100514

Ugur Calis , Merve Aydogan , Guldane Cengiz Seval , Klara Dalva , Selami Kocak Toprak

High expression of immune checkpoint markers may leukemic cells to evade the immune system in AML. This study aimed to investigate the relationship between PD-1/PD-L1 expression and treatment outcomes in AML patients.. The study included 21 patients and 18 healthy volunteers. Non-responders exhibited significantly higher PD-1 expression (MFI) in CD3+ and CD4+ T cells. At the time of diagnosis, bone marrow samples from patients exhibited a significantly higher proportion of PD-1 expression in CD3+, CD4+, and CD8+ T lymphocytes than peripheral blood samples. The results revealed an association between PD-1/PD-L1 expression and clinical traits in newly diagnosed AML patients.

免疫检查点标记的高表达可能导致白血病细胞逃避免疫系统。本研究旨在探讨AML患者PD-1/PD-L1表达与治疗结果的关系。该研究包括21名患者和18名健康志愿者。无应答者在CD3+和CD4+ T细胞中表现出更高的PD-1表达（MFI）。在诊断时，患者骨髓样本中CD3+、CD4+和CD8+ T淋巴细胞中PD-1的表达比例明显高于外周血样本。结果揭示了新诊断的AML患者的PD-1/PD-L1表达与临床特征之间的关联。

引用次数: 0

Case report: Rechallenge with gilteritinib after acute pancreatitis in FLT3-positive AML 病例报告：flt3阳性AML患者急性胰腺炎后再用吉替尼治疗

IF 0.7 Q4 HEMATOLOGY

Leukemia Research Reports

Pub Date : 2025-01-01 Epub Date: 2025-02-13 DOI: 10.1016/j.lrr.2025.100503

Taner TAN , Genco Gençdal , Ümit Barbaros Üre , Olga Meltem AKAY

引用次数: 0

Targeting menin for precision therapy in high-risk acute myeloid leukemia 以 Menin 为靶点，对高风险急性髓性白血病进行精准治疗。

IF 0.7 Q4 HEMATOLOGY

Leukemia Research Reports

Pub Date : 2025-01-01 Epub Date: 2024-12-18 DOI: 10.1016/j.lrr.2024.100495

Abdur Jamil , Zaheer Qureshi , Zain Mary El-amir , Gillian Kupakuwana-Suk , Hamzah Akram , Mohsin Ahmad , Eric Huselton

Objective

This mini-review provides an overview of the current evidence for Revumenib, a first-in-class menin inhibitor, in treating AML with KMT2A rearrangements or NPM1 mutations. This therapy represents a promising advancement by selectively disrupting leukemogenic pathways.

Summary

The clinical promise of Revumenib in genetically defined AML highlights its potential role in shaping the future treatment landscape. This mini-review underscores the need for ongoing trials to define optimal dosing, safety protocols, and combination therapies, with the ultimate goal of establishing Revumenib as a standard of care for high-risk AML subsets.

目的：这篇小型综述概述了Revumenib（一种一流的menin抑制剂）治疗KMT2A重排或NPM1突变的AML的现有证据。这种疗法通过选择性地破坏白血病发生途径代表了一种有希望的进步。总结：Revumenib在基因定义AML中的临床前景突出了其在塑造未来治疗前景方面的潜在作用。这一小型综述强调了正在进行的试验以确定最佳剂量、安全方案和联合治疗的必要性，最终目标是将Revumenib建立为高风险AML亚群的标准治疗。

引用次数: 0

首页上一页

下一页尾页

类型

全部化学•材料生命科学医学物理工程技术环境•农林材料科学地球科学法学管理学化学环境科学与生态学计算机科学教育学经济学农林科学人文科学生物学数学物理与天体物理心理学综合性期刊其他工业工程理学历史学农学文学信息工程

数据库

全部 ACS Publications Elsevier ieeexplore Springer The Royal Society of Chemistry Wiley

期刊

Leukemia Research Reports

全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.

﹀